In a lab outside Boston, scientists are engineering molecules to do something unprecedented: slip deep into lung tissue, latch onto disease-causing proteins, and mark them for cellular destruction. This is the core mission of Alveus Therapeutics, a stealthy biotech now stepping into the spotlight with a $160 million venture round to propel its pipeline of inhaled targeted protein degraders. The company, founded in 2024 by a team of protein degradation veterans and pulmonary disease specialists, is tackling a fundamental problem in respiratory medicine. While biologics like monoclonal antibodies have revolutionized other fields, delivering large, potent drugs effectively to the lung has remained a formidable challenge. Alveus aims to change that by marrying the precision of protein degraders—often dubbed 'molecular garbage trucks'—with inhalation technology, creating therapies that could precisely dismantle pathological proteins in conditions like idiopathic pulmonary fibrosis (IPF) and severe asthma without systemic side effects. This move taps directly into the white-hot trend of expanding protein degradation beyond oncology. The field, pioneered by companies like Arvinas and Kymera, is rapidly seeking new therapeutic areas and novel delivery routes. Alveus's hefty Series B suggests investors are betting that the lungs could be the next major frontier for this modality, offering a lucrative market with high unmet need. With the new capital, Alveus is poised to advance its lead candidate, ALV-101, toward clinical proof-of-concept. The coming 18 months will be critical, as the company prepares IND-enabling studies and seeks to demonstrate that its localized degradation approach can safely hit targets previously considered 'undruggable' in the respiratory tract.